In numerous pre-clinical and clinical trials, anti-TIGIT antibody therapy has achieved significant tumor-suppressive efficacy (Joller et al., 2011; Zhang et al., 2018; Preillon et al., 2021). The gene discussed is TIGIT; the disease is neoplasm.